Javascript must be enabled to continue!
In vivo evaluation of a nanotechnology-based microshunt for filtering glaucoma surgery
View through CrossRef
AbstractTo carry out the preclinical and histological evaluation of a novel nanotechnology-based microshunt for drainage glaucoma surgery. Twelve New Zealand White rabbits were implanted with a novel microshunt and followed up for 6 weeks. The new material composite consists of the silicone polydimethylsiloxane (PDMS) and tetrapodal Zinc Oxide (ZnO-T) nano-/microparticles. The microshunts were inserted ab externo to connect the subconjunctival space with the anterior chamber. Animals were euthanized after 2 and 6 weeks for histological evaluation. Ocular health and implant position were assessed at postoperative days 1, 3, 7 and twice a week thereafter by slit lamp biomicroscopy. Intraocular pressure (IOP) was measured using rebound tonometry. A good tolerability was observed in both short- and medium-term follow-up. Intraocular pressure was reduced following surgery but increased to preoperative levels after 2 weeks. No clinical or histological signs of inflammatory or toxic reactions were seen; the fibrotic encapsulation was barely noticeable after two weeks and very mild after six weeks. The new material composite PDMS/ZnO-T is well tolerated and the associated foreign body fibrotic reaction quite mild. The new microshunt reduces the IOP for 2 weeks. Further research will elucidate a tube-like shape to improve and prolong outflow performance and longer follow-up to exclude medium-term adverse effects.
Springer Science and Business Media LLC
Title: In vivo evaluation of a nanotechnology-based microshunt for filtering glaucoma surgery
Description:
AbstractTo carry out the preclinical and histological evaluation of a novel nanotechnology-based microshunt for drainage glaucoma surgery.
Twelve New Zealand White rabbits were implanted with a novel microshunt and followed up for 6 weeks.
The new material composite consists of the silicone polydimethylsiloxane (PDMS) and tetrapodal Zinc Oxide (ZnO-T) nano-/microparticles.
The microshunts were inserted ab externo to connect the subconjunctival space with the anterior chamber.
Animals were euthanized after 2 and 6 weeks for histological evaluation.
Ocular health and implant position were assessed at postoperative days 1, 3, 7 and twice a week thereafter by slit lamp biomicroscopy.
Intraocular pressure (IOP) was measured using rebound tonometry.
A good tolerability was observed in both short- and medium-term follow-up.
Intraocular pressure was reduced following surgery but increased to preoperative levels after 2 weeks.
No clinical or histological signs of inflammatory or toxic reactions were seen; the fibrotic encapsulation was barely noticeable after two weeks and very mild after six weeks.
The new material composite PDMS/ZnO-T is well tolerated and the associated foreign body fibrotic reaction quite mild.
The new microshunt reduces the IOP for 2 weeks.
Further research will elucidate a tube-like shape to improve and prolong outflow performance and longer follow-up to exclude medium-term adverse effects.
Related Results
Childhood glaucoma profile in a Southwestern Ethiopia tertiary care center: a retrospective study
Childhood glaucoma profile in a Southwestern Ethiopia tertiary care center: a retrospective study
Abstract
Background
Childhood glaucoma is a major cause of childhood blindness worldwide. The profile of childhood glaucoma has not been well characterized in sub-Saharan ...
Cross-sectional Survey to Determine the Awareness and Uptake of Glaucoma Surgery
Cross-sectional Survey to Determine the Awareness and Uptake of Glaucoma Surgery
Introduction
: This study aimed to determine the awareness and uptake of surgery as a treatment option in patients with glaucoma on medical treatment.
...
Trend of glaucoma internal filtration surgeries in a tertiary hospital in China
Trend of glaucoma internal filtration surgeries in a tertiary hospital in China
AIM: To evaluate the trend of glaucoma internal filtration surgeries for inpatients between 2015 and 2021 at the Eye Hospital of Wenzhou Medical University.
METHODS: A review of th...
PRESERFLO MicroShunt
PRESERFLO MicroShunt
Abstract
The PRESERFLO® MicroShunt (Santen Pharmaceutical Co. Ltd., Osaka, Japan), formerly called the InnFocus MicroShunt®, is a trans-scleral device that shunts aqueous humour fr...
Profile of Newly Referred Glaucoma Patients to the Largest Tertiary Eye Care Hospital in Saudi Arabia
Profile of Newly Referred Glaucoma Patients to the Largest Tertiary Eye Care Hospital in Saudi Arabia
Abstract
Purpose: To report the profile of newly referred glaucoma patients to the largest tertiary eye care hospital in Saudi Arabia.
Patients and Methods: Medical record...
Proportion of Glaucoma among Voluntary People Coming for Glaucoma Screening Program at Jimma University Department of Ophthalmology, Jimma, Ethiopia
Proportion of Glaucoma among Voluntary People Coming for Glaucoma Screening Program at Jimma University Department of Ophthalmology, Jimma, Ethiopia
BACKGROUND: Glaucoma is the second leading cause of blindness worldwide. Glaucoma screening has been controversial, and much of the controversy has centered on the value of mass or...
Staphylococcus Capitus Blebitis Following Preserflo MicroShunt Implantation
Staphylococcus Capitus Blebitis Following Preserflo MicroShunt Implantation
Purpose:
To report a case of early-onset blebitis following Preserflo MicroShunt implantation.
Patients and Methods:
Case ...
Profile of pediatric glaucoma patients in Shanghai Eye, Ear, Nose and Throat Hospital
Profile of pediatric glaucoma patients in Shanghai Eye, Ear, Nose and Throat Hospital
BackgroundThe extent of our knowledge of the epidemiology of pediatric glaucoma in China is limited. To better characterize the epidemiology of pediatric glaucoma in eastern China,...

